

Date: 14.08.2023

To BSE Limited P.J.Towers, Dalal Street, Mumbai – 400001 BSE - Code : 532660

National Stock Exchange of India Ltd. Exchange Plaza,Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company - reg.

The Board of Directors of the Company at its meeting held on August 14, 2023 inter alia, have approved / resolved/ taken note of the following:

- 1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30, 2023 attached herewith;
- 2. Auditors's Limited Review Report on the Un-audited Financial Statements of the Company for the Quarter ended June 30, 2023.
- 3. To file an application to the office of the Registrar of Companies, Bangalore, Karnataka, seeking an extension of time by three months for the convening of AGM for the Financial Year 2022-23

The Board Meeting concluded at 20.30 P.M.

This is for your information and records.

Yours faithfully For VIVIMED LABS LIMITED

SANTOSH VARALWAR MANAGING DIRECTOR

Vivimed Labs Limited.

CIN: L02411KA1988PLC009465 Registered Office: #78/A, Kolhar Industrial Area, Bidar, Karnataka - 585 403, India. T +91 [0] 8482-232045, F +91 [0] 8482-232436 Email: contact@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

NCC House, 4th Floor [Western Wing], Sy. No.64, Madhapur, Hyderabad, Telangana – 500 081, India. GSTIN: 36AAACV6060A1ZQ T +91(0] 40-6608-6608, F +91(0] 40-6608-6699

_	VIVIMED LA				
	UNAUDITED CONSOLIDATED FINANCIAL RE	SULTS FOR THE QUARTER E	ENDED 30.06.2023		
					Rs. In Millio
. No.	Particulars		3 Months Ended		
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Income From Operations	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income From Operations				
1	Revenue from operations	353.51	370.30	501.05	1,870
	Total revenue from operations	353.51	370.30	501.05	1.870.
2	Other Income	1.12	6.83	0.82	9.
3	Total Revenue (1+2)	354.63	377.13	501.87	1,880.0
4	Expenses				
а	Cost of material consumed	174.65	227.12	272.71	1,099.,
b	Purchases of Stock- in- Trade	7.75	0.59		8.
C	Changes in inventories of finished goods work in progress and stock-in-Trade	(1.55)	1.592.46	3.42	1.607.
d	Employee Benefit Expenses	76.27	88.18	66.64	326.
e	Finance Costs	106.61	85.19	93.14	359.
f	Depreciation and Amortisation Expenses	46.99	959.23	44.48	1,084.
g	Other Expenses	99.66	104.88	244.04	702.
	Total Expenses	510.38	3,057.65	724.43	5,187.
5	Profit before tax (3-4)	(155.75)	(2.680.52)	(222.56)	(3.306.
6	Tax expenses Current Taxes		-	-	
	Deferred Taxes		(20.65)	(0.52)	(21.
	Total tax expenses	-	(20.65)	(0.52)	(21
7	Profit for the period /Year before non-controlling interest (5-6)	(155.75)	(2,659.87)	(222.04)	(3,285.
8	Non-controlling interest				
9	Profit for the period/year (7-8)	(155.75)	(2.659.87)	(222.04)	(3,285
10	Other comprehensive income		and the second se		-10
	Items that will not be reclassified to profit or loss, net of tax		40.65	-	40.
	Items that will be reclassified to profit or loss, net of tax	-	(0.03)		(0.
	Total other comprehensive income	-	40.62		40
11	Non-controlling interest	-		4	
12	Other comprehensive income attributable to shareholders(10+11)	-	40.62	-	40
	Total comprehensive income attributable to:	(155 75)	(2 (10 25)	(222.0.4)	(2.24)
	Shareholders of the Company Non-controlling interest	(155.75)	(2,619.25)	(222.04)	(3,244
	Total Comprehensive income	(155.75)	(2.619.21)	(222.04)	(3,244
13	Paid up Equity Share Capital	165.83	165.83	165.83	165
	Other equity				
15	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)				
	(a) Denila	(1.60)	(22.00)	A 20	
	(a) Basic(b) Diluted	(1.88)	(32.08)	(2.68)	(39)
	In the second se	(1.82)	(31.14)	(2.60)	(3

NOTES

1. The above unaudited consolidated financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 14, 2023. The statutory auditors of the Company have carried out a limited review on consolidated financial results..

2. These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed wider Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder (IND-AS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").

3. Defaulted in repayment of Loans Outstanding; The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,868.94 million as on 30.06.2023 as per books of Account. An amount of Rs. 106.14 million has been accounted as Provision for interest on the loan amount outstanding as on 30.06.2023. All the loan accounts outstanding as on 30.06.2023 are classified as NPA by the banks.

4. The subsidiaries considered for the consolidated financial statements for the Quarter ended June 30, 2023 are Finoso Pharma Private Limited, Vivimed Labs USA Inc, Vivimed Holdings Ltd and Vivimed Labs Mauritius Ltd.

5. In line with provisions of Ind AS 108 Operating segments, the Group has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Group.

6. Corresponding numbers of previous period / year have been regrouped, wherever necessary.



For VIVIMED LABS LIMITED 1 N RJ IREC R

Place : Hyderabad Date : 14-08-2023

	VIVIMED LABS I	IMITED				
SEGMENT-WISE CONS	OLIDATED FINANCIAL RESU	ULTS FOR THE QUAR	TER ENDED 30.06.2023			
	Rs. In Millic					
		3 Months Ended				
Particulars	30.06.2023	31.03.2023	30.06.2022	31.03.2023		
	(Unaudited)	(Audited)	(Unaudited)	(Audited)		
1. Segment Revenue						
(net sales/income from each segment						
should be disclosed under this head)						
a.Speciality Chemicals Business	15.22	59.96	47.48	112.21		
b.Pharma Business	339.41	317.18	453.57	1.768.46		
Total	354.63	377.13	501.05	1,880.68		
Less, Inter Segment Revenue						
Net sales / Income from Operations	354.63	377.13	501.05	1,880.68		
2.Segment Results (Profit) (+) / Loss (-)						
before tax and interest from each segment						
a.Speciality Chemicals Business	(12.70)	(1,106.65)	(63.03)	(1,274.51)		
b.Pharma Business	(36.44)	(1,488.67)	(66.39)	(1,672.97)		
Total	(49.15)	(2,595.33)	(129.42)	(2,947.48)		
Less: 1.Interest	106.61	85.19	93.14	359.03		
2. Other Un-allocable Expenditure	-	-	-			
3.Un-allocable Income	-	-	-	-		
Total Profit Before Tax	(155.75)	(2,680.52)	(222.56)	(3,306.51		

Segmental capital employed

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangebility across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad Date : 14-08-2023



For VIVIMED LABS LIMITED (SANTOSH VARALWAR) MANAGING DIRECTOR

	VIVIMED	ABS LIMITED			
	UNAUDITED STANDALONE FINANCIAL R	ESULTS FOR THE QUARTER	ENDED 30.06.2023		
	n d d		114 1 5 1 1		Rs. In Millio
No.	Particulars		3 Months Ended		
					Previous Year Ended 31.03.2023
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income From Operations				
1	Revenue from Operations	329.99	397.21	473.64	1,768.25
	Total revenue from operations	329.99	397.21	473.64	1,768.25
2	Other Income	0.08		0.81	2.39
3	Total Revenue (1+2)	330.06	397.21	474.45	1,770.65
4	Expenses				
а	Cost of material consumed	177.18	227.54	279.09	1,078.7
b	Purchases of Stock- in- Trade				
C	Changes in inventories of finished goods work in progress and stock-in-Trade	(1.55)	1,592.46	3.42	1.607.59
d	Employee Benefit Expenses	65.72	79.17	56.58	286.9
е	Finance Costs	106.14	80.69	92.57	352.80
ſ	Depreciation and Amortisation Expenses	44.85	950.72	42.33	1,069.1
8	Other Expenses	91.55	135.76	219.84	676.7.
	Total Expenses	483.88	3,066.34	693.83	5,071.91
5	Profit before tax (3-4)	(153.82)	(2,669.13)	(219.38)	(3,301.26
6	Tax Expenses				
	Current Taxes	-	-	-	-
	Deferred Taxes Total tax expenses		(20.65) (20.65)	(0.52)	(21.17
7	Profit for the period /Year (5-6)	(153.82)	(2,648.48)	(218.86)	(21.17) (3,280.08
8	Other Comprehensive income	(155.62)	(2,040.40)	(210.00)	(3,200.00
U	Items that will not be reclassified to profit or loss, net of tax		40.52		40.52
	Items that will be reclassified to profit or loss, net of tax				10.00
	Total other comprehensive income	-	40.52		40.52
9	Total comprehensive income (7+8)	(153.82)	(2,607.96)	(218.86)	(3,239.57
10	Paid up Equity Share Capital	165.83	165.83	165.83	165.8.
11	Other equity		0.000		10010
12	Earnings per Share (before Extraordinary Items) (of Rs2/- each)				
	(a) Basic	(1.86)	(31.94)	(2.65)	(39.50
	(b) Diluted	(1.80)	(31.01)	(2.56)	(38.40

NOTES

1. The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 14, 2023 The statutory auditors of the Company have carried out a limited review on standalone financial results..

2. These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND-AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").

3. Defaulted in repayment of Loans Outstanding:

The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,868.94 million as on 30.06.2023 as per books of Account. An amount of Rs. 106.14 million has been accounted as Provision for interest on the loan amount outstanding as on 30.06.2023. All the loan accounts outstanding as on 30.06.2023 are classified as NPA by the banks.

4. In line with provisions of IND-AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.

5. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad Date : 14-08-2023



For VIVIMED L BSTIMUTED w (SANTOSH VARALWAR) MANAGING DECTOR

	VIVIMED LAB	S LIMITED			
SEGMENT-WIS	E STANDALONE FINANCIAL RES	SULTS FOR THE QUARTER	ENDED 30.06.2023		
				Rs. In Million	
		3 Months Ended			
Particulars	30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022	31.03.2023 (Audited)	
			(Unaudited)		
1. Segment Revenue					
(net sales/income from each segment					
should be disclosed under this head)					
a.Speciality Chemicals Business	15.22	59.96	47.48	112.21	
b.Pharma Business	314.84	337.25	426.16	1,658.44	
Total	330.06	397.21	473.64	1,770.65	
Less, Inter Segment Revenue					
Net sales / Income from Operations	330.06	397.21	473.64	1,770.65	
2.Segment Results (Profit) (+) / Loss (-)					
before tax and interest from each segment					
a.Speciality Chemicals Business	(12.70)	(1,106.65)	(63.03)	(1,274.51)	
b.Pharma Business	(34.97)	(1.481.78)	(63.79)	(1.673.95)	
Total	(47.68)	(2,588.44)	(126.81)	(2,948.46)	
Less: 1.Interest	106.14	80.69	92.57	352.80	
2. Other Un-allocable Expenditure		-	-		
3. Un-allocable Income		-	-		
Total Profit Before Tax	(153.82)	(2,669.13)	(219.38)	(3,301.26)	

19

Segmental capital employed As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangebility across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad Date : 14-08-2023





Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors M/s Vivimed Labs Limited.

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s Vivimed Labs Limited.** (the "Holding Company") and its subsidiaries (the "Holding Company" and its subsidiaries together referred to as "the Group"), for the quarter ended 30th June, 2023("the Statement") attached herewith, being submitted by the "Holding Company" pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the listing regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on "the Statement" based on our review.

We have conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of



all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Attention is invited to the following observations:

Financial Year 2023-24 (For Quarter ending 30.06.2023):

a) The Holding company is not regular in remittance of statutory dues with appropriate authorities. The Statutory Dues outstanding for the period 01-04-2023 to 30-06-2023 are as follows:

S. No	Particulars	Amount (in Rs.)
1	TDS	Rs. 3,06,240/-
2	Professional Tax	Rs. 1,46,050/-
3	Provident Fund	Rs. 32,74,812/-
4	Employee State Insurance	Rs. 4,15,406/-
	Total	Rs. 41,42,508/-

- b) The Holding company has written off Inventory amounting to Rs.809.3 million during the FY 2022-23, the same as impact on the financial results through opening balances of Inventory considered for Changes in Inventory for the quarter ended 30.06.2023.
- c) The Holding Company has capitalised the CWIP and has Impaired its Plant and Machinery during the FY 2022-23, the same has impact on the Financial Results through opening balances of respective PPE considered for Depreciation accounted for the quarter ended 30.06.2023.
- d) The Holding company has defaulted in Repayment of dues to Banks and Financial Institutions, the provision for Interest payables has been accounted in the books of account and the same was disclosed in the financial results as Finance Cost amounting to Rs.106.14 million for Quarter Ended 30.06.2023.

Financial Year 2022-23:

a) The Holding Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,762.80 million as on 31.03.2023.





- b) The Holding Company has impaired its Plant & Machinery during the F.Y 2022-23 by an amount of Rs. 892.80 million. We are unable to comment upon the correctness of Closing balances of PPE and methods employed for calculating the impairment on Plant & Machinery.
- c) The Holding Company has written down the Inventories amounting to Rs. 809.3 million during the F.Y 2022-23. In absence of any competent third-party report and valuation method adopted by the management in respect of written down of inventories, and closing balances, we are unable to comment on the discrepancies.
- d) In absence of confirmations from the Related parties, we are unable to comment upon the correctness and validity of Related party transactions disclosed in the notes to financial statements with respect to the Investments, Receivables and Payables.
- a) The Holding Company has capitalised its Capital Work in Progress and closing balance is amounting to Rs. 206.65 million during the F.Y 2022-23, we are unable to comment upon the correctness of the same.
- e) In the absence of fair valuation of the investments, we are unable to comment upon the carrying value and whether any provision for impairment in the value of investments is required.
- f) The Holding Company has been defaulted in the payment of various undisputed Statutory Dues amounting to Rs. 135.52 million as on 31.03.2023 with appropriate authorities.
- g) As per our opinion, the compliance of Standards on Internal Audit, internal Controls/ internal audit system pertains to the operations of the company are not commensurate with the size & diversity of the activities of the company and the apparent weakness has been reported to the management for their appropriate measures to be taken in order to strengthen operations of the company.





h) The State Bank of India appointed Forensic Auditors, the said audit is under progress and the final outcome is yet to come.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

"The Statement" includes the results of the following entities:

- (a) Finoso Pharma Private Limited.
- (b) Vivimed Labs USA inc.
- (c) Vivimed Holdings Ltd.
- (d) Vivimed Labs Mauritius Ltd.

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs. 32.10 million and total net profit/(loss) after tax of Rs. (1.93) million for the period 01-04-2023 to 30-06-2023 as considered in the "Statement" whose interim financial results and other financial information have not been reviewed by their auditors;

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on "the Statement", in so far as it relates to the affairs of subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.





Tel. : (91-40) 2311 9499 E-mail : pcnassociates@yahoo.com

Our conclusion on "the Statement" in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management.

For P C N & Associates Chartered Accountants Firm's Registration No: 016016S

1 Hyderal FRN:016016S K Gopala Krishna

Partner Membership No. 203605 UDIN: 23203605BGRTYQ9559

Place: Hyderabad Date: 14-08-2023



Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors M/s Vivimed Labs Limited

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **M/s Vivimed Labs Limited** ("the Company") for the quarter ended 30 June 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the listing regulations").

The preparation of "the Statement", which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ("Ind AS 34"), 'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on "the Statement" based on our review.

We have conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope that an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





Attention is invited to the following observations:

Financial Year 2023-24 (For Quarter ending 30.06.2023):

 a) The company is not regular in remittance of statutory dues with appropriate authorities. The Statutory Dues outstanding for the period 01-04-2023 to 30-06-2023 are as follows:

S. No	Particulars	Amount (in Rs.)
1	TDS	Rs. 3,06,240/-
2	Professional Tax	Rs. 1,46,050/-
3	Provident Fund	Rs. 32,74,812/-
4	Employee State Insurance	Rs. 4,15,406/-
	Total	Rs. 41,42,508/-

- b) The company has written off Inventory amounting to Rs.809.3 million during the FY 2022-23, the same as impact on the financial results through opening balances of Inventory considered for Changes in Inventory for the quarter ended 30.06.2023.
- c) The Company has capitalised the CWIP and has Impaired its Plant and Machinery during the FY 2022-23, the same has impact on the Financial Results through opening balances of respective PPE considered for Depreciation accounted for the quarter ended 30.06.2023.
- d) The company has defaulted in Repayment of dues to Banks and Financial Institutions, The provision for Interest payables has been accounted in the books of account and the same was disclosed in the financial results as Finance Cost amounting to Rs.106.14 Million for Quarter Ended 30.06.2023.

Financial Year 2022-23:


- a) The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,762.80 million as on 31.03.2023.
- b) The Company has impaired its Plant & Machinery during the F.Y 2022-23 by an amount of Rs. 892.80 million. We are unable to comment upon the





correctness of Closing balances of PPE and methods employed for calculating the impairment on Plant & Machinery.

- c) The company has written down the Inventories amounting to Rs. 809.3 million during the F.Y 2022-23. In absence of any competent third-party report and valuation method adopted by the management in respect of written down of inventories, and closing balances, we are unable to comment on the discrepancies.
- d) In absence of confirmations from the Related parties, we are unable to comment upon the correctness and validity of Related party transactions disclosed in the notes to financial statements with respect to the Investments, Receivables and Payables.
- e) The Company has capitalised its Capital Work in Progress and closing balance is amounting to Rs. 206.65 million during the F.Y 2022-23, we are unable to comment upon the correctness of the same.
- f) In the absence of fair valuation of the investments, we are unable to comment upon the carrying value and whether any provision for impairment in the value of investments is required.
- g) The company has been defaulted in the payment of various undisputed Statutory Dues amounting to Rs. 135.52 million as on 31.03.2023 with appropriate authorities
- h) As per our opinion, the compliance of Standards on Internal Audit, internal controls/ internal audit system pertains to the operations of the company are not commensurate with the size & diversity of the activities of the company and the apparent weakness has been reported to the management for their appropriate measures to be taken in order to strengthen operations of the company.
- i) The State Bank of India appointed Forensic Auditors, the said audit is under progress and the final outcome is yet to come.





P C N & ASSOCIATES CHARTERED ACCOUNTANTS Plot No. "N Heights" Ground Floor, Software Layout Unit

Tel. : (91-40) 2311 9499 E-mail : pcnassociates@yahoo.com

Cyberabad, Hyderabad - 500 081. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying "Statement", prepared in accordance with the recognition and measurement principles laid down in the aforesaid "Ind AS 34" prescribed under castion 100 for

1:160165

34" prescribed under section 133 of the companies Act,2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates Chartered Accountants Firm's Registration No: 016016S

K Gopala Krishna Partner M. No. 203605 UDIN: 23203605BGRTYP9643

Place: Hyderabad Date: 14-08-2023